Previous studies reported comparable stent patency between covered self-expandable metallic stents (SEMS) and uncovered SEMS (UCS) for palliation of malignant gastric outlet obstruction (GOO). The aim of this study was to evaluate the effi cacy and safety of the newly developed WAVE-covered SEMS (WCS), which has an anti-migration design, compared with UCS in gastric cancer patients with symptomatic GOO.
INTRODUCTION
Th e endoscopic self-expandable metallic stent (SEMS) has become a feasible alternative to surgery for the palliation of inoperable malignant gastric outlet obstruction (GOO) and has more favorable short-term clinical outcomes (1) (2) (3) . However, the clinical effi cacy of SEMS has been compromised by several unresolved problems (4) (5) (6) (7) . For uncovered SEMS, long-term patency is mainly hindered by tumor ingrowth through the metal Covered Metallic Stents With an Anti-Migration Design vs. Uncovered Stents for the Palliation of Malignant Gastric Outlet Obstruction: A Multicenter, Randomized Trial mesh and consequent luminal stenosis (which has a frequency of 12-30%) (8) (9) (10) (11) . For covered SEMS, stent migration occurs at a frequency of 16-25% and is a major obstacle to stent patency (12) (13) (14) . Despite much lower tumor ingrowth rates in covered stents, their high migration rates lead to comparable clinical outcomes between covered and uncovered SEMS for the palliation of malignant GOO. Currently, a few randomized trials have compared clinical outcomes between uncovered stents and partially or fully covered stents in patients with malignant GOO, and these trials have reported comparable stent patency between the two stents ( 13, 15, 16 ) .
To reduce migration and achieve a higher stent patency rate, various modifi cations (using anti-migration designs) of covered SEMS have been attempted. Th us far, no prospective randomized trial has demonstrated that covered SEMS have superior clinical outcomes to uncovered SEMS for the palliation of malignant GOO ( 13, (15) (16) (17) (18) .
Recently, we developed a new covered SEMS with anti-migration properties (WAVE stent). WAVE stent was designed to have reduced radial force and indentation in the central part of the SEMS, uncovered fl ared portions at both ends, and a lasso at the proximal end that enables optimization of the stent position aft er deployment. Th e aim of this study was to evaluate the effi cacy and safety of the newly developed WAVE stent compared with uncovered SEMS for the palliation of malignant GOO in patients with inoperable gastric cancer.
METHODS

Study design
Th is study was a prospective, multicenter, double-arm, patientblinded, randomized trial and was conducted at fi ve tertiary care centers. Th e study was approved by the Institutional Review Boards of each of the participating centers and was conducted according to the guidelines described in the Declaration of Helsinki for biomedical research involving human subjects (Clinical trial registration number: ClinicalTrials.gov NCT01646476). Between July 2012 and July 2014, 147 patients who were admitted due to symptoms of GOO caused by inoperable gastric cancer were assessed for eligibility as described below. Of these 147 patients, 102 fulfi lled the eligibility criteria and were enrolled in the study aft er providing written informed consent.
Eligibility criteria
Patients with an initial diagnosis of gastric cancer were assessed using the following inclusion criteria: (i) the presence of pathologically confi rmed gastric adenocarcinoma that was inoperable due to distant metastasis or severe comorbidity; (ii) upper endoscopy or abdominal computed tomography fi ndings that were consistent with GOO at the distal antrum, pylorus, or duodenal bulb; (iii) the presence of GOO symptoms (early satiety, nausea, or vomiting) and a Gastric Outlet Obstruction Scoring System (GOOSS) score ≤2 (no oral intake, 0; liquids only, 1; soft solids, 2; low residue or full diet, 3) ( 19 ); and (iv) aged 20-80 years. Th e exclusion criteria were as follows: (i) inability to provide informed consent; (ii) multiple-level bowel obstruction confi rmed on radiographic studies such as small bowel series or abdominal computed tomography; (iii) previous history of stent insertion or endoscopic dilation for GOO treatment; (iv) prior gastric surgery; (v) inability to undergo an upper endoscopy; and (vi) Borrmann type IV advanced gastric cancer.
Randomization and masking
Patients who fulfi lled the eligibility criteria were randomized in a 1:1 ratio to the uncovered SEMS (UCS) group (BONASTENT, Standard Sci Tech, Seoul, Korea) or the WAVE-covered SEMS (WCS) group (BONASTENT, Standard Sci Tech), using a centralized, web-based randomization system. Th e allocation sequence was computer generated, with a block size of four. Patients had no knowledge of the stent type to which they were allocated.
Features of WCS
Th e newly developed WCS is a partially covered stent made of a nitinol hook and a cross wire structure with a diameter of 20 mm ( Figure 1 ). WCS has several features that prevent migration. Th e stent body is indented in the central portion and thus has a bumpy and wavy external appearance, providing mechanical resistance to migration. Th e central part of the stent was designed to have reduced radial force compared with its proximal and distal parts (244 gf for the central part and 284 gf for the proximal and distal parts). Reduction of the radial force in the central part of the stent may help to prevent migration by allowing fi xation at the stricture site. Platinum radiopaque markers were sutured in place in order to identify the central and bumpy portion of the stent, aiding in accurate placement. Th e WCS is completely covered with a silicone membrane in the middle; both the proximal and distal ends are uncovered and fl ared. In addition, this stent has a lasso at the proximal end to facilitate repositioning aft er deployment. Th e stents are available in 6, 8, 10, 12, 14, and 16 cm lengths with diameters of 18/24 mm (body/fl are) at full expansion.
Procedures
SEMS placement was performed with a therapeutic endoscope (working channel ≥3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. Th e length of the stricture was assessed either endoscopically or fl uoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. Aft er the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Th en, the stent was deployed under continuous fl uoroscopic control. For the WCS group, the stent was repositioned aft er deployment using the lasso under fl uoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent, which reduced radial force and indentation. Endoscopists evaluated the fl uoroscopic fi ndings observed during stent placement to evaluate the location of the stent relative to the location of the ampulla of Vater. Th e stent occluded the ampulla of Vater if it bridged the distal half of the second portion of the duodenum ( 20 ) . Stent positioning was confi rmed endoscopically and fl uoroscopically.
Follow-up after SEMS placement
If the SEMS insertion was technically successful without any immediate complications, the patient was allowed to drink clear water on the day of the procedure. Th e diet was advanced gradually to a low-residue diet within 2 days, provided that the patient tolerated the diet and obstructive symptoms did not recur. Bilirubin (normal range, 0.2-1.2 mg/dl) and alkaline phosphate (normal range, 40-120 IU/l) levels before and aft er stent placement were evaluated. Abdominal plain fi lms were checked daily for at least 3 days aft er stent placement to confi rm full expansion and proper positioning of the inserted SEMS. Relief of obstructive symptoms was assessed 72 h aft er stent placement using the GOOSS. Aft er discharge, patients underwent scheduled follow-up at 8 weeks and 16 weeks aft er deployment of the SEMS at the hospital where the stent was placed. At the 8-week follow-up, symptoms were evaluated with the GOOSS. In addition, patients underwent upper endoscopy and abdominal plain fi lm examination to check for stent dysfunction, including stenosis or migration. At the 16-week follow-up, the GOOSS score and abdominal plain fi lms were checked. Whenever obstructive symptoms recurred aft er stent placement, patients underwent upper endoscopy and radiologic examinations (computed tomography or abdominal plain fi lms). In addition to the scheduled 8-week and 16-week follow-ups, patients receiving chemotherapy underwent periodic follow-ups with abdominal computed tomography to assess treatment response. Data on chemotherapy aft er stent insertion were collected for subsequent analyses. Clinical data were recorded until the patient's death or until the censoring date of 30 November 2014 (the date of the last follow-up).
Defi nitions and end points
Technical success was defi ned as adequate placement of the SEMS across the stenotic area, as confi rmed by a combination of endoscopy and fl uoroscopy. Clinical success was defi ned as relief of obstructive symptoms with an improvement of at least one point in the GOOSS score at 72 h aft er technically successful SEMS placement. Failure of SEMS patency was defi ned as the recurrence of obstructive symptoms with a decrease in the GOOSS score due to stent dysfunction. Stent dysfunction included stent stenosis by tumor ingrowth or overgrowth, stent migration, collapse, and fracture. Stent stenosis was considered if the patient had recurrence of obstructive symptoms, and the endoscope could not be passed through the lumen of the stent. Stent migration was considered if the stent had moved from its initial position and did not cover the entire stenosis. Th e primary end point of the present study was 8-week stent patency aft er SEMS insertion; secondary end points included 16-week stent patency and overall stent patency.
Statistical analysis
Th e primary analysis was a superiority comparison between WCS and UCS for the primary end point of 8-week stent patency using an intention-to-treat (ITT) analysis. In addition, treatment effi cacy data, including overall survival, overall patient survival without stent dysfunction, and duration of stent patency, were analyzed in the ITT population. We also performed a modifi ed ITT (mITT) analysis. Th e mITT population included patients who underwent UCS or WCS placement and completed the 8-week follow-up for stent patency ( 21, 22 ) . Th is mITT population (with secondary end point information) was analyzed for stent dysfunction pattern.
Based on a previous study of covered and uncovered SEMSs for palliation of malignant GOO ( 13 ) , it was hypothesized that the 8-week stent patency rate in the WCS group would be superior, with a 29% diff erence in the patency rate compared with the UCS group (89% vs. 60%). To demonstrate a 29% diff erence in the stent patency rate using a statistical power of 80% and with the assumption of a two-sided error rate of 0.05, the protocol required at least 82 randomly assigned patients. Aft er considering loss to follow-up, we determined that a sample size of 100 patients would be adequate.
Categorical data were analyzed with the χ 2 -test or Fisher's exact test. Continuous data were analyzed with the unpaired t-test. In each assigned group, the duration of stent patency was estimated using the Kaplan-Meier method. Patients who had not experienced recurrent obstructive symptoms due to stent dysfunction were censored at the date of the last follow-up or the date of death. Th e Kaplan-Meier method was used to evaluate overall survival, with living patients censored at the date of the last follow-up. Th e Kaplan-Meier method was also used to evaluate overall patient survival without stent dysfunction (the time to stent dysfunction or patient death); living patients without stent dysfunction were censored at the date of the last follow-up. Th e log-rank test was used to compare the UCS and the WCS groups. Predictive factors for stent patency were evaluated using the Cox proportional hazards model, which included patient age, gender, the location of the stricture site, the baseline GOOSS score, baseline performance status, disease stage, the type of stent, the length of the stent, and whether post-stent chemotherapy was administered. Stratifi ed analyses with regard to the 8-week and 16-week stent ENDOSCOPY Stents for Malignant Gastric Outlet Obstruction patency were performed in subgroups that were pre-defi ned according to age, gender, the location of the stricture, the baseline GOOSS score, the length of the stent, and the receipt of poststent chemotherapy. Linear modeling was used to evaluate the consistency of treatment eff ects among the subgroups by testing for interactions between the treatment group and the clinically relevant subgroups. P-values of <0.05 were considered statistically signifi cant. Adjusted Bonferroni P-values were used for multiple comparisons with control for experimental errors due to multiple statistical tests.
RESULTS
Patient characteristics
A total of 147 inoperable gastric cancer patients with symptomatic GOO were screened; 102 patients were randomly assigned to receive either a UCS (51 patients) or a WCS (51 patients). A fl ow diagram for the trial is provided in Figure 2 . Th e baseline clinical and endoscopic characteristics are presented in Table 1 . Th e UCS and WCS groups were well balanced in both the ITT and mITT populations. Th ere were no signifi cant diff erences between the two groups with respect to tumor location, stent length, baseline GOOSS distribution, Eastern Cooperative Oncology Group (ECOG) performance status, or the receipt of post-stent chemotherapy.
Technical and clinical success
Th e UCS and the WCS groups demonstrated comparable results in terms of both the technical and clinical success rates. Technical success of UCS and WCS placement was achieved in 96.1% (49/51) and 98.0% (50/51) of the patients, respectively ( P =0.558). Among patients undergoing technical success, fi ve patients in the UCS group and two patients in the WCS group failed to achieve clinical success ( P =0.240; Figure 2 ). Because all obstruction was related Table 2 and Figure 4 demonstrate the pattern of stent dysfunction up to the 8-week and the 16-week follow-ups in the mITT population. At the 8-week follow-up, both the stent patency and re-intervention rates were comparable between the UCS and the WCS groups. Stent patency rates were 62.7 and 72.5% in the UCS and the WCS groups in the ITT population ( Figure 3a ) and 86.5 and 88.1% in mITT population ( Figure 3b ), respectively ( P =0.290 for ITT population and P =0.830 for mITT population). Th e re-intervention rates were 19.6% in both groups in the ITT analysis ( Figure 3c ) and 10.8% and 9.5% in the UCS and WCS groups, respectively, in the mITT analysis ( Figure 3d ; P =1.000 in ITT population and P =0.850 for mITT population). Up to the 8-week follow-up, stent migration rates were 5.4 and 9.5% in the UCS and the WCS groups, to distal gastric cancer only, we encountered no cases of biliary obstruction associated with stent placement bridging the ampulla of Vater. According to the laboratory tests, the pre-procedural and post-procedural bilirubin (1.60±0.14 vs.1.54±0.21 mg/dl) and alkaline phosphate levels (204.1±22.9 vs.217.5±17.8 mg/dl) did not diff er.
8-week and 16-week stent patency and patterns of stent dysfunction
Before analysis of the primary outcome at 8 weeks aft er stent, gastric cancer-related death occurred in six patients (three patients in the UCS group and three patients in the WCS group, 5.9% each). In addition, two patients (3.9%) in the WCS group underwent unexpected palliative surgery due to massive tumor bleeding ( Figure 2 ). Table 2 and Figure 4 ). At the 16-week follow-up, the WCS group had superior outcomes to UCS group in terms of stent patency and re-intervention rates, in contrast to the 8-week outcomes. Stent patency rates were 41.2 and 68.6% in the UCS and the WCS groups in the ITT population ( Figure 3a ) and 56.8 and 83.3% in the mITT population ( Figure 3b ), respectively ( P =0.005 for the ITT population and P =0.009 for the mITT population). Th ere was no signifi cant diff erence between re-intervention rates between the two groups according to the ITT analysis aft er Bonferroni's correction (39.2% vs. 23.5%; Figure 3c ). Th e UCS group had a higher re-intervention rate than the WCS group in mITT analyses (37.8% vs. 14.3%, P =0.016; Figure 3d ). Th e stent dysfunction pattern up to the 16-week follow-up also diff ered from the pattern of stent failure up to 8 weeks aft er stent placement. Th e UCS group had a signifi cantly higher stent restenosis rate than the WCS group (37.8% vs. 7.1%, P =0.001). In contrast to the stent restenosis rate, stent migration rates up to the 16-week follow-up were comparable between the two groups (5.4% for the UCS group and 9.5% for the WCS group; P =0.491; Table 2 and Figure 4 ).
No stent-associated signifi cant adverse events, such as bleeding or perforation, were reported during the follow-up period in either group.
Overall stent patency and survival
Th e mean total duration of follow-up was 141.7±66.7 days in the UCS group and 149.2±71.9 days in the WCS group. At the time of the fi nal evaluation (30 November 2014), 25 patients (49.0%) in the UCS group and 19 patients (37.3%) in the WCS group had died. Supplementary Figure S1 online shows Kaplan-Meier curves for the duration of stent patency, overall survival, and overall survival without stent dysfunction in the ITT population. Th e WCS group had a signifi cantly longer cumulative duration of stent patency compared with the UCS group ( Supplementary Figure S1A ) . Th e overall survival time was comparable between the UCS and the WCS groups ( Supplementary Figure S1B ) . Overall patient survival without stent dysfunction (the time to stent dysfunction or patient death) was longer in the WCS group than in the UCS group, with borderline statistical signifi cance ( Supplementary Figure S1C ) . Table 3 shows the multivariate analysis of predictive factors for stent patency in the ITT population, using a Cox proportional hazards model. At the 8-week follow-up, only post-stent chem- 
Predictive factors for stent patency
DISCUSSION
To date, there have been many eff orts to develop covered SEMS with anti-migration properties, with the goal of improving longterm stent patency. Despite these eff orts, however, no prospective randomized trial has demonstrated that covered SEMS are superior to uncovered SEMS for the palliation of malignant GOO ( 13, 15, 16 ) . A few randomized trials, small comparative studies, and case series have been published regarding pyloric and duodenal stents for malignant GOO ( Table 4 ). In accordance with the results of previous studies, we found that the 8-week stent patency rate was comparable between the WCS and the UCS groups in the ITT population. At the 16-week follow-up, however, the WCS group showed superior outcomes to the UCS group in both the stent patency rate and the re-intervention rate. Th is is the fi rst prospective randomized study demonstrating superior clinical outcomes of covered SEMS to uncovered SEMS for the palliation of GOO in patients with inoperable gastric cancer.
Analyses of the 8-week and 16-week stent dysfunction patterns showed that the superior clinical outcomes in the WCS group were primarily driven by comparable stent migration rates and signifi cantly lower stent restenosis rates compared with the UCS group. Stent migration rates remained stable over the follow-up period and were comparable between the two groups at both the 8-week and 16-week follow-up visits. Based on these results, it can be assumed that if patients undergoing WCS placement do not experience the stent migration in the early post-procedure phase, favorable long-term stent patency can be expected. Th ese results also indicate that the anti-migration properties of the WCS efficiently and durably prevented stent migration and contributed to long-term overall stent patency and overall survival without stent dysfunction.
In the multivariate analysis, stent type and post-stent chemotherapy were identifi ed as independent predictors of 16-week stent patency. Previous studies also reported comparable results regarding the protective eff ect of post-stent chemotherapy against stent dysfunction (23) (24) (25) .
Th e strengths of this study were its prospective and randomized design and the scheduled follow-up protocol, with radiologic otherapy was identifi ed as an independent predictor of stent patency. At the 16-week follow-up, stent type as well as poststent chemotherapy were identifi ed as independent predictors of stent patency. WCS placement reduced the risk of stent dysfunction, with a relative risk of 0.51 compared with UCS placement. Post-stent chemotherapy also reduced the risk of stent dysfunction. To evaluate the consistency of stent placement eff ects among the subgroups, we performed subgroup analyses of factors aff ecting the stent patency. Th e pre-specifi ed subgroup analysis did not show heterogeneity of WCS treatment eff ects on either 8-or 16-week stent patency rates ( Supplementary Figure  S2A, B ) . Lee et al.
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Previous studies have reported comparable stent patency between covered self-expandable metallic stents (SEMS) and uncovered SEMS for the palliation of malignant gastric outlet obstruction (GOO).
✓ Covered SEMS are prone to stent migration, which compromises durable stent patency.
WHAT IS NEW HERE
✓ WAVE-covered SEMS (WCS) with an anti-migration design showed signifi cantly more durable long-term stent patency than uncovered SEMS for the palliation of GOO in patients with inoperable gastric cancer.
✓ The superior clinical outcomes in the WCS group were primarily driven by comparable stent migration rates and signifi cantly lower stent restenosis rates compared with the uncovered SEMS group.
stent patency and overall patient survival without stent dysfunction. Th e consistency of the fi ndings over the follow-up period suggests that the results of the present study are reliable. Second, our results may not be generalizable to GOO in pancreatic cancer patients, who have a poor prognosis and frequently have obstructions in the distal duodenal area.
In conclusion, WCS demonstrated signifi cantly more durable long-term stent patency compared with UCS for the palliation of GOO in patients with inoperable gastric cancer. Th e superior clinical outcomes in the WCS group were primarily driven by comparable stent migration rates and signifi cantly lower stent restenosis rates compared with the UCS group. Newly developed WCS could be considered as the promising stent option for the durable palliation of symptomatic GOO in patients with inoperable gastric cancer.
